Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
But breaking Pfizer and Merck’s duopoly will not be easy.
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?